Japanese pharma outsources earlier as peptide development challenges grow
April 29, 2026Peptide therapies, peptide
Japanese pharmaceutical companies are increasingly engaging contract development and manufacturing organisations (CDMOs) earlier in the drug development process, as the …
Study suggests phospholipid therapy may impact fatty liver disease outcomes
April 29, 2026Research and Development fatty liver disease, phospholipid therapy
A randomised clinical trial has reported that treatment with essential phospholipids (Essentiale) may reduce liver fat and improve symptoms in …
FDA signals support for development of psychedelic therapies in mental healthmental health
April 28, 2026Neurology, mental health
The US Food and Drug Administration (FDA) has announced a series of measures aimed at supporting the development of psychedelic-based …
New web series explores path from ophthalmic research to patient access
April 28, 2026Research and Development Opthalmology
A new YouTube web series has been launched to examine how ophthalmic innovations progress from early research through to approved …
EMA backs plozasiran for rare lipid disorder with high pancreatitis risk
April 27, 2026Research and Development The European Medicines Agency (EMA), plozasiran
The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Redemplo (plozasiran) to treat adults with familial chylomicronaemia …
Study explores speech as marker in rare neurodegenerative disease
April 27, 2026Research and Development SynaptixBio, neurodegenerative disease
SynaptixBio has highlighted the potential of speech analysis as a non-invasive way to track disease progression in neurodegenerative conditions, as …
Ofichem brings all brands under single trading name
April 23, 2026Ofichem
Ofichem has brought all its brands under its trading name to provide its customers a single integrated offering. The company …
Carvolix strengthens its Board of Directors, advisory board and governance structure
April 23, 2026Carvolix
Carvolix (formerly Affluent Medical) has announced it is strengthening its Board of Directors, advisory board and governance structure. As part …
Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC
April 22, 2026University of Huddersfield’s NHIC
Dr Zubir Ahmed MP, the Under-Secretary of State for Health Innovation and Safety, recently visited the newly opened Emily Siddon …
Incyclix Bio announces new additions to the Board
April 22, 2026Incyclix Bio
Incyclix Bio has announced that it has raised $5m in additional funds for its Series B financing from new investor …
Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO
April 21, 2026Remedy Plan Therapeutics
Remedy Plan Therapeutics has appointed Jotin Marango as Chief Financial and Business Officer (CFO & CBO). “Joti brings a strong …
Xilio Therapeutics appoints Cheryl R Blanchard to Board
April 20, 2026Xilio Therapeutics
Xilio Therapeutics has announced the appointment of Cheryl R Blanchard to the company’s board of directors. The company also announced …
Kayentis and RWS partner to improve clinical trial data confidence
April 17, 2026Research and Development RWS, kayentis
Kayentis and RWS have announced a partnership aimed at improving confidence in clinical trial data for neuroscience and other complex …
MHRA expands its pioneering AI Airlock programme with £3.6m funding boost
April 16, 2026Research and Development
The Medicines and Healthcare products Regulatory Agency (MHRA) has secured new funding to expand its AI Airlock programme, aimed at …
Ardena opens new US bioanalytical laboratory
April 15, 2026Business Services
Ardena has announced that its new GLP bioanalytical laboratory in Somerset, New Jersey in the US is operational and supporting …
Gesynta Pharma doses first patient in endometriosis phase 2 trial
April 14, 2026Research and Development Gesynta Pharma, endometriosis
Gesynta Pharma has dosed the first patient in its phase 2 clinical proof-of-concept trial of vipoglanstat. The trial, NOVA, is …
Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says
April 13, 2026Astellas Pharma, menopause
Final draft NICE guidance has recommended Veoza (fezolinetant), made by Astellas Pharma, to treat moderate to severe menopausal hot flushes …
Sandoz launches allergy relief nasal spray in Germany and Switzerland
April 9, 2026Ear Nose & throat
Sandoz has launched its azelastine and fluticasone fixed-dose-combination (FDC) nasal spray in Germany and Switzerland. In Germany the FDC over …
Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer
April 9, 2026Oncology
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the updated prescribing information for Daiichi Sankyo’s Enhertu (trastuzumab), a …
Trelleborg to take part in Medtec Japan 2026
April 8, 2026Manufacturing and Production
Trelleborg Medical Solutions will showcase its latest engineered polymer solutions for demanding medical, biotech and pharmaceutical applications at Medtec Japan …
Latest content
FibroFind appoints Lee Borthwick as CEO
